

Nanexa extends collaboration agreement with Applied Materials

Nanexa AB (publ) today announced that the company has expanded its collaboration agreement with Applied Materials, Inc., through an amendment regulating commercial arrangements, paving the way for potential future license agreements with customers in the pharmaceutical industry.

The agreement sets the framework for utilizing the respective strengths of the two companies to accelerate advanced drug development in relation to potential future agreements covering both licensing and commercial production of drugs. The collaboration builds on Nanexa's expertise and exclusivity in the field of parenteral drug development and Applied's deep expertise in materials engineering and advanced manufacturing technologies.

In December 2020, Nanexa signed a collaboration agreement with Applied Materials for joint development of coating technology, in order for Nanexa to secure larger scale manufacturing capabilities for its ALD-coated long-acting injectable drugs.

This agreement builds in its entirety on the previously communicated collaboration agreement.

"We highly value the collaboration with Applied Materials as it helps accelerate our efforts to take a project from idea all the way to market production," says David Westberg, CEO of Nanexa. "The expanded agreement follows the completion of Nanexa's new pilot plant and gives us good momentum as we seek to engage further with customers.

For additional information, please contact:

David Westberg – CEO, Nanexa AB (publ)

Phone: +46 70 942 83 03

Email: david.westberg@nanexa.se

www.nanexa.com

Erik Penser Bank is the company's Certified Adviser and can be reached on +46 8 463 83 00, email: certifiedadviser@penser.se

About Nanexa AB (publ)

Nanexa is a pharmaceutical company developing parenteral drug products based on the proprietary and innovative drug delivery system PharmaShell® – the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. Nanexa develops its own products and also has collaboration agreements with several pharma companies, among others AstraZeneca.

Nanexa's share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).

Press Release
21 July 2022 12:50:00 CEST



Attachments

[Nanexa extends collaboration agreement with Applied Materials](#)